OTSA101 is an anti-FZD10 antibody and has been developed as novel cancer therapy for synovial sarcoma. FZD10, which was identified through genome-wide analysis by the group of Professor Yusuke Nakamura (former Director of Human genome center, Institute of Medical Science,The University of Tokyo ) is frequently and highly upregulated in synovial sarcoma but being hardly detectable in normal organs.

OTSA101 specifically binds to FZD10 in cancer cells. Radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation in mouse xenograft model.

In addition, OTSA101 is designated as an orphan drug for treatment of soft tissue sarcoma by Food and Drug Administration (FDA) respectively.

back to top